Emd Serono Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMD SERONO, and when can generic versions of EMD SERONO drugs launch?
EMD SERONO has nine approved drugs.
There are thirteen US patents protecting EMD SERONO drugs.
There are one hundred and ninety-five patent family members on EMD SERONO drugs in forty-two countries and eighty-nine supplementary protection certificates in sixteen countries.
Summary for Emd Serono
| International Patents: | 195 |
| US Patents: | 13 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 9 |
Drugs and US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,658,643 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | RX | Yes | Yes | 7,713,947 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-001 | Mar 3, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-001 | Oct 13, 2000 | 6,475,521 | ⤷ Try a Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 7,605,121 | ⤷ Try a Trial |
| Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-003 | Dec 23, 1987 | 4,820,738 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101544624 | ⤷ Try a Trial |
| South Africa | 201001023 | ⤷ Try a Trial |
| European Patent Office | 2805723 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1827461 | C201830015 | Spain | ⤷ Try a Trial | PRODUCT NAME: CLADRIBINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1212; DATE OF AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1212; DATE OF FIRST AUTHORISATION IN EEA: 20170822 |
| 1506211 | 179 5017-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116 |
| 1506211 | 122014000070 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
